Abstract: Systems and methods for treating ocular disorders are disclosed. One system has a delivery instrument, with a non-linear axis, configured to be inserted into an anterior chamber of an eye and moved to a location proximate a physiologic outflow pathway of the eye. The delivery instrument carries an implant that has a distal end sized for insertion into tissue such that aqueous humor drains from the anterior chamber to the physiologic outflow pathway. One method involves inserting a non-linear portion of a delivery device into the anterior chamber to position an implant within the eye. Another method involves using a delivery device with a curved distal portion to implant an implant at a location communicating with the physiologic outflow pathway. The delivery can be through a corneal incision and the implant can comprise a drug.

Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.

Abstract: A pipette check station for checking the calibration or service status of a pipette includes an RFID reader, a user interface with a display and buttons, and a digital interface to connect the check station to additional equipment; the check station optionally further includes provisions to hold pipettes for storage and to charge electronic pipettes held thereupon.

Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.

Abstract: Surgical methods and related medical devices for treating ocular disorders are disclosed. Some methods relate to delivering an implant within an eye, and involve providing an elongate guide device, such as, a flexible guide member or a guide wire. A distal end of the guide device can be advanced into an anterior chamber of an eye, or through at least a portion of a site of resistance along a physiologic outflow pathway of the eye, or from an anterior chamber of the eye to a location proximate a physiologic outflow pathway of the eye. The implant is advanced along the guide device toward the guide device distal end, and is positioned to conduct aqueous humor between the anterior chamber and the physiologic outflow pathway.

Abstract: Systems and methods for treating ocular disorders are disclosed. One system has a delivery instrument, with a non-linear axis, configured to be inserted into an anterior chamber of an eye and moved to a location proximate a physiologic outflow pathway of the eye. The delivery instrument carries an implant that has a distal end sized for insertion into tissue such that aqueous humor drains from the anterior chamber to the physiologic outflow pathway. One method involves inserting a non-linear portion of a delivery device into the anterior chamber to position an implant within the eye. Another method involves using a delivery device with a curved distal portion to implant an implant at a location communicating with the physiologic outflow pathway. The delivery can be through a corneal incision and the implant can comprise a drug.

Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.

Abstract: Compositions and methods are provided for enhancing the expression of human beta defensin 2 (HBD2) in human colon epithelium cells. The method comprises orally administering a composition comprising hyaluronan, where said hyaluronan has a molecular weight within the range of about 35 kDa.

Abstract: There is provided a content automation system and a method for use by the content automation system for issuing a content management message for use in a program stream. In one implementation, such a content automation system comprises a processor and a memory, and a stream messaging module residing in the memory. The stream messaging module is configured to issue the content management message by embedding a command sequence as metadata in a container data structure, and inserting the container data structure into the program stream. The command sequence authorizes a replacement of program stream content.

Abstract: There is provided a content automation system and a method for use by the content automation system for issuing a content management message for use in a program stream. In one implementation, such a content automation system comprises a processor and a memory, and a stream messaging module residing in the memory. The stream messaging module is configured to issue the content management message by embedding a command sequence as metadata in a container data structure, and inserting the container data structure into the program stream. The command sequence authorizes a replacement of program stream content.

Abstract: A pipette check station for checking the calibration or service status of a pipette includes an RFID reader, a user interface with a display and buttons, and a digital interface to connect the check station to additional equipment; the check station optionally further includes provisions to hold pipettes for storage and to charge electronic pipettes held thereupon.

Abstract: Compositions and methods for treating glaucoma by restoring the filtration capabilities of the endothelial lining of Schlemm's canal are provided. More particularly, methods of lowering intraocular pressure are disclosed, where a subject in need of such treatment is administered a therapeutically effective amount of a composition. In various embodiments, the composition may include tyrosine or L-DOPA conjugated to an ascorbic acid, an enzyme, a nucleic acid encoding an enzyme, or trabecular meshwork cells.

Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.

Abstract: Drainage of body fluid from an area of undesirably high pressure can be accomplished by interconnecting an artificial non-blood fluid conduit with the vascular system. For example, an artificial non-blood fluid conduit can be inserted into the eye to fluidly interconnect the anterior chamber with a location of lower pressure. The conduit can have a growth factor for stimulating growth of new blood vessels in the location of lower pressure to connect the new blood vessels with the non-blood fluid conduit.

Abstract: An apparatus and method for electrical charge balancing when generating a stimulus during functional neural stimulation is presented. A stimulus pulse is generated (cathodic or anodic), and after a selected delay a charge compensating pulse is generated of an opposite polarity. The electrode circuit discontinuously examines electrode voltage after termination of the stimulus pulse, and utilizes this voltage to determine how long to extend the width of the charge compensating pulse. The electrode circuit thus performs accurate electrical charge cancellation to remove residual charges from the electrode by precisely controlling pulse width for an opposing polarity compensating pulse that need not have the same current level as the stimulus pulse.

Abstract: A pipette check station for checking the calibration or service status of a pipette includes an RFID reader, a user interface with a display and buttons, and a digital interface to connect the check station to additional equipment; the check station optionally further includes provisions to hold pipettes for storage and to charge electronic pipettes held thereupon.

Abstract: Drainage of body fluid from an area of undesirably high pressure can be accomplished by interconnecting an artificial non-blood fluid conduit with the vascular system. For example, an artificial non-blood fluid conduit can be inserted into the eye to fluidly interconnect the anterior chamber with a location of lower pressure. The conduit can have a growth factor for stimulating growth of new blood vessels in the location of lower pressure to connect the new blood vessels with the non-blood fluid conduit.

Abstract: Devices, systems and methods for needle free injection include a multi-use needle-free injection device comprising reversibly connected proximate and distal sections, wherein the proximate section comprises a power supply, actuator, circuitry and a housing, and the distal section comprises a disposable nozzle tip prefilled with an injectate, a chemical energetic device, and a dual seal piston barrier between the energetic device and the injectate, wherein the proximate and distal sections and their components are operably linked and configured for single-hand injecting of the injectate.

Abstract: An embodiment of a system for shunting aqueous humor from an anterior chamber of an eye includes an implant having an elongated body made of biocompatible material and a delivery device. At least a portion of the elongated body is implantable between a sclera and a ciliary body while the elongated body resides entirely within the confines of the sclera and a cornea with the proximal end of the implant being configured to reside within an anterior chamber angle and a lumen extending from at least one inlet port of the implant, through at least a portion of the elongated body, to one or more outlet ports of the implant so as to drain fluid from the anterior chamber toward a choroid of the eye. The delivery device includes an elongated member with a curved distal end portion to deliver the implant using an ab interno procedure.